 Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.260.820 D12.776.624.776.775 D12.776.660.825 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- Oncoprotein p53
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- TP53 Protein
- Cellular Tumor Antigen p53
- p53 Antigen
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 2 | 0 | 2 | | 1993 | 2 | 0 | 2 | | 1994 | 1 | 2 | 3 | | 1995 | 3 | 3 | 6 | | 1996 | 5 | 5 | 10 | | 1997 | 2 | 3 | 5 | | 1998 | 3 | 5 | 8 | | 1999 | 1 | 0 | 1 | | 2000 | 3 | 4 | 7 | | 2001 | 3 | 4 | 7 | | 2002 | 9 | 9 | 18 | | 2003 | 7 | 3 | 10 | | 2004 | 8 | 2 | 10 | | 2005 | 6 | 5 | 11 | | 2006 | 8 | 5 | 13 | | 2007 | 3 | 7 | 10 | | 2008 | 4 | 10 | 14 | | 2009 | 5 | 4 | 9 | | 2010 | 9 | 3 | 12 | | 2011 | 9 | 7 | 16 | | 2012 | 5 | 7 | 12 | | 2013 | 4 | 1 | 5 | | 2014 | 7 | 5 | 12 | | 2015 | 7 | 6 | 13 | | 2016 | 6 | 4 | 10 | | 2017 | 8 | 4 | 12 | | 2018 | 4 | 6 | 10 | | 2019 | 7 | 5 | 12 | | 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Diakite B, Kassogue Y, Dolo G, Kassogue O, Keita ML, Joyce B, Neuschler E, Wang J, Musa J, Traore CB, Kamate B, Dembele E, Nadifi S, Isichei M, Holl JL, Murphy R, Doumbia S, Hou L, Maiga M. Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis. BMC Med Genet. 2020 07 03; 21(1):142.
-
Colom B, Alcolea MP, Piedrafita G, Hall MWJ, Wabik A, Dentro SC, Fowler JC, Herms A, King C, Ong SH, Sood RK, Gerstung M, Martincorena I, Hall BA, Jones PH. Spatial competition shapes the dynamic mutational landscape of normal esophageal epithelium. Nat Genet. 2020 06; 52(6):604-614.
-
Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, Ito Y, Ueno T, Ohno S, Nakamura Y, Takahashi S. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(2):331-341.
-
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
-
Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
-
Setia N, Ahn S, Han HS, Park DY, Lauwers GY. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma. Hum Pathol. 2019 12; 94:64-70.
-
Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, He M, Xiao Q, Sun M, Olopade OI, Zhao L, Wei M. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
-
Mei L, Alikhan M, Mujacic I, Parilla M, Antic T. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates. Acta Cytol. 2019; 63(5):438-444.
-
Godley LA. FouNdER mutations confer risk for leukemias. Blood. 2019 06 20; 133(25):2636-2638.
-
Todorova PK, Fletcher-Sananikone E, Mukherjee B, Kollipara R, Vemireddy V, Xie XJ, Guida PM, Story MD, Hatanpaa K, Habib AA, Kittler R, Bachoo R, Hromas R, Floyd JR, Burma S. Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. Cancer Res. 2019 07 15; 79(14):3749-3761.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|